Ensysce Biosciences, Inc. (ENSC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Ensysce Biosciences reported revenue of $5.1M, down 2.8% from $5.2M the year before. Net income was -$10.2M (a -200.8% net margin), or -$3.98 per diluted share. Operating margin was -202.1%. Operating activities generated -$7.8M of cash, leaving -$7.9M of free cash flow. At fiscal year end, Ensysce Biosciences held $7.5M in total assets against $4.6M in total liabilities, including $4.3M of cash and equivalents.
Open the full interactive Ensysce Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Ensysce Biosciences Key Stats
| Share Price | $0.57 |
|---|---|
| Market Cap | $7.5M |
| Revenue YoY Growth | -2.8% |
| 52-Week Range | $0.25 – $2.57 |
| Shares Outstanding | 13.0 million (basic, 2026 Q2) |
Ensysce Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $3.5M | $2.5M | $2.2M | $5.2M | $5.1M |
| Operating Income | -$1.4M | -$19.9M | -$24.2M | -$10.7M | -$6.7M | -$10.2M |
| Pre-Tax Income | $2.6M | -$29.1M | -$24.2M | -$10.6M | -$8.0M | -$10.2M |
| Income Tax | $244,493 | — | — | — | — | — |
| Net Income | $2.4M | -$29.1M | -$24.2M | -$10.6M | -$8.0M | -$10.2M |
| Diluted EPS | $1368.00 | -$5328.00 | — | -$70.35 | -$11.45 | -$3.98 |
Ensysce Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $493,104 | $1.9M | $960,999 | $1.2M |
| Net Income | -$3.7M | -$2.8M | -$3.6M | -$2.6M |
| Diluted EPS | -$1.29 | -$1.08 | -$0.52 | -$0.20 |
Ensysce Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $12.3M | $3.1M | $1.1M | $3.5M | $4.3M |
| Current Assets | $226,464 | $15.7M | $5.3M | $2.3M | $5.3M | $7.2M |
| Total Assets | $12.9M | $16.4M | $5.9M | $2.7M | $5.6M | $7.5M |
| Current Liabilities | $260,404 | $16.5M | $9.5M | $3.3M | $2.2M | $4.6M |
| Total Long-Term Debt | $225,000 | $20.8M | $4.7M | — | — | — |
| Total Liabilities | $7.8M | $24.6M | $9.9M | $3.4M | $2.2M | $4.6M |
| Shareholders' Equity | $5.0M | -$7.9M | -$3.7M | -$322,858 | $3.7M | $3.2M |
Ensysce Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$864,439 | -$8.2M | -$17.9M | -$10.8M | -$7.5M | -$7.8M |
| Cash From Investing | $183.4M | — | $4,500 | — | — | -$123,643 |
| Cash From Financing | -$183.6M | $20.3M | $8.8M | $8.8M | $9.9M | $8.7M |
| Free Cash Flow | — | — | — | — | — | -$7.9M |
Figures from Ensysce Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ensysce Biosciences financials page for every line item.
Ensysce Biosciences Company Profile
| Ticker | ENSC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | La Jolla, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001716947 |
Frequently Asked Questions
What was Ensysce Biosciences' revenue in fiscal 2025?
Ensysce Biosciences (ENSC) reported revenue of $5.1M for fiscal 2025.
What is Ensysce Biosciences' annual revenue history?
Ensysce Biosciences' annual revenue by fiscal year: 2020: $0; 2021: $3.5M; 2022: $2.5M; 2023: $2.2M; 2024: $5.2M; 2025: $5.1M.
What was Ensysce Biosciences' net income in fiscal 2025?
Ensysce Biosciences reported net income of -$10.2M for fiscal 2025.
What was Ensysce Biosciences' earnings per share (EPS) in fiscal 2025?
Ensysce Biosciences' diluted EPS was -$3.98 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ensysce Biosciences generate in fiscal 2025?
Ensysce Biosciences generated -$7.9M of free cash flow in fiscal 2025.
What was Ensysce Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Ensysce Biosciences reported revenue of $1.2M.
How many shares of Ensysce Biosciences are outstanding?
Ensysce Biosciences reported a weighted average of 13.0 million basic shares outstanding in 2026 Q2.
What is Ensysce Biosciences' market cap?
Based on its latest closing price, Ensysce Biosciences (ENSC) has a market capitalization of about $7.5M.
When does Ensysce Biosciences' fiscal year end?
Ensysce Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Ensysce Biosciences headquartered?
Ensysce Biosciences lists its business address in La Jolla, California in its SEC filings.